Ovarian Cancer · LIVING RESEARCH LIBRARY

Ongoing Research for Ovarian Cancer Using Advanced Alternative Medicine

Explore positive published findings by substance, cancer biology, treatment interaction and quality-of-life outcome.

Every entry includes the original study title, year, concise finding and a direct PubMed link.

Call 1.800.923.7878

Ask About Your Ovarian Cancer Case

Tell us the diagnosis, stage, biomarkers, current treatment plan and research questions you want to understand. Our Patient Care Team will follow up personally.

Prefer to speak now?
Call 1.800.923.7878

Explore this cancer section

Ovarian Cancer

Living research library · positive published findings

Research organized by substance and finding

Browse 25 source-linked studies with the full title, publication year, research focus and a concise finding. Select any linked substance to move directly to its corresponding Sunridge page.

Artesunate triggers ferroptosis in ovarian cancer via GP130-mediated IL-6/STAT3/OTUB1/SLC711 axis disruption.

2025 · Apoptosis and cell death

Artesunate (ART) has demonstrated relatively broad-spectrum anticancer effects recently, yet whether it can suppress OC by inducing ferroptosis, along with the underlying mechanisms, warrants further exploration.

Open study on PubMed →

Dihydroartemisinin inhibits metastatic potential and cancer stemness by modulating the miR-200b-BMI-1/VEGF-A axis in ovarian cancer.

2025 · Metastasis and invasion

Here we demonstrated that dihydroartemisinin (DHA), a derivative of the antimalarial drug artemisinin, inhibits CSC characteristics, tumor neovascularization and resistance to carboplatin via a microRNA-dependent mechanism in ovarian cancer.

Open study on PubMed →

Berberine enhances the sensitivity of radiotherapy in ovarian cancer cell line (SKOV-3).

2023 · Treatment response

Berberine, a well-known isoquinoline alkaloid derivative, has a varied range of pharmacological effects.

Open study on PubMed →

Berberine modulates ovarian cancer autophagy and glycolysis through the LINC01123/P65/MAPK10 signaling axis.

2024 · Metastasis and invasion

The anti-proliferative and anti-metastatic effects of berberine on ovarian cancer cells were investigated using CCK-8 assays, scratch assays, EDU proliferation assays, and assays related to glycolysis and autophagy.

Open study on PubMed →

Curcumin derivative NL01 induces ferroptosis in ovarian cancer cells via HCAR1/MCT1 signaling.

2023 · Apoptosis and cell death

CCK-8 was used to detect curcumin and derivative IC50, crystalline violet staining was used to detect the proliferation inhibition effect of NL01 in ovarian cancer, western blot and qPCR were used to detect downstream related molecular expression changes, Transwell and survival curve assays were used to detect malignant phenotypic.

Open study on PubMed →

Curcumin induces ferroptosis in ovarian cancer cells through the Nrf2/GPX4 regulation axis.

2026 · Metastasis and invasion

Our results demonstrated that curcumin inhibited proliferation, migration, and invasion of SK-OV-3 and A2780 cells in a dose-dependent manner, while inducing apoptosis and ferroptosis, as evidenced by elevated reactive oxygen species (ROS), MDA, Fe2+ levels, and depletion of GSH.

Open study on PubMed →

Curcumin inhibits ovarian cancer progression by regulating circ-PLEKHM3/miR-320a/SMG1 axis.

2021 · Apoptosis and cell death

Circ-PLEKHM3 overexpression exacerbated the effect of curcumin on ovarian cancer cell proliferation and apoptosis, as well as anti-tumor effect.

Open study on PubMed →

Curcuminoids WM03 inhibits ovarian cancer cisplatin-resistant cells proliferation and reverses cisplatin resistance by targeting DYRK2.

2025 · Metastasis and invasion

Curcumin has been shown to effectively inhibit the proliferation and invasion of ovarian cancer cells but its bioavailability restricts its application.

Open study on PubMed →

RETRACTION NOTICE: Curcumin and resveratrol inhibit chemoresistance in cisplatin-resistant epithelial ovarian cancer cells via targeting P13K pathway.

2022 · Treatment response

The study reports rETRACTION NOTICE: Curcumin and resveratrol inhibit chemoresistance in cisplatin-resistant epithelial ovarian cancer cells via targeting P13K pathway.

Open study on PubMed →

Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer.

2023 · Cancer biology and response

Fenbendazole (FZ) has potential anti-cancer effects, but its poor water solubility limits its use for cancer therapy.

Open study on PubMed →

Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study.

2024 · Apoptosis and cell death

Here, we investigated the anticancer effects of fenbendazole (FBZ), a benzimidazole compound, on the regulation of apoptosis and mitotic catastrophe in A2780 and SKOV3 human epithelial ovarian cancer cells.

Open study on PubMed →

Ginsenoside 20(S)-Rg3 upregulates SQLE to reprogram cholesterol metabolism of ovarian cancer cells.

2025 · Metastasis and invasion

Silencing of SQLE attenuated the inhibitory effects of 20(S)-Rg3 on ovarian cancer cell proliferation in vitro and in vivo, as well as cell migration, invasion, and cholesterol synthesis.

Open study on PubMed →

Ivermectin Augments the Anti-Cancer Activity of Pitavastatin in Ovarian Cancer Cells.

2023 · Treatment response

When the drugs were combined and assessed in cell growth assays, ivermectin showed synergy with pitavastatin in 3 cell lines and this was most evident in COV-318 cells (combination index ~ 0.6).

Open study on PubMed →

Melatonin changes energy metabolism and reduces oncogenic signaling in ovarian cancer cells.

2024 · Metabolism and redox biology

Because melatonin (Mel) has antitumor actions, we investigated its impact on energy metabolism and kinase signaling in OC cells (SKOV-3 and CAISMOV-24).

Open study on PubMed →

The proteomic landscape of ovarian cancer cells in response to melatonin.

2022 · Immune and inflammatory signaling

We conclude that melatonin significantly alters the proteome of SKOV-3 cells by changing proteins involved with the immune response and mitochondrial metabolism.

Open study on PubMed →

Association between vaginal microbiota and the progression of ovarian cancer.

2023 · Cancer biology and response

Local therapeutic intervention with a broad spectrum of antibiotics was effective in reversing microbiota dysbiosis and suppressing carcinogenic progression.

Open study on PubMed →

Disruption of the Gut Microbiota Confers Cisplatin Resistance in Epithelial Ovarian Cancer.

2022 · Treatment response

Cecal transplants of microbiota derived from control-treated mice was sufficient to ameliorate chemoresistance and prolong survival of ABX-treated mice, indicative of a gut-derived tumor suppressor.

Open study on PubMed →

Potential role of microbiota in ovarian cancer treatment.

2025 · Treatment response

Recent research indicates that gut, vaginal, and uterine microbiota play a critical role in the response to treatments of ovarian cancer, and particularly in chemotherapy, anti-angiogenic therapy, and PARP inhibitors.

Open study on PubMed →

Unintended Consequences of Antibiotic Therapy on the Microbiome Delivers a Gut Punch in Ovarian Cancer.

2022 · Cancer biology and response

The study by Chambers and colleagues in this issue of Cancer Research provides mechanistic insights into how disrupting the gut microbiome with broad-spectrum antibiotics negatively influences the survival of patients with ovarian cancer and highlights the impact of the gut microbiome on tumor progression and response to therapy.

Open study on PubMed →

Identification of Quercetin as a Natural MMP1 Inhibitor for Overcoming Cisplatin Resistance in Epithelial Ovarian Cancer.

2025 · Metastasis and invasion

In vitro experiments demonstrated that quercetin effectively inhibited the proliferation, apoptosis resistance, invasion, and migration of cisplatin-resistant EOC cells.

Open study on PubMed →

Quercetin combined with shTERT induces apoptosis in ovarian cancer via the P53/Bax pathway, and RGD-MSN/QR/shTERT nanoparticles enhance the therapeutic efficacy.

2025 · Apoptosis and cell death

Quercetin(QR) has been shown to inhibit the cell cycle and induce the apoptosis in various types of tumors.

Open study on PubMed →

Quercetin induces ferroptosis in ovarian cancer through regulating HSPB1/Notch1 pathway.

2026 · Apoptosis and cell death

Quercetin inhibited cell proliferation and colony formation, triggered apoptosis, and promoted ferroptosis in A2780 and SKOV3 cells, marked by GPX4 downregulation and malondialdehyde levels increase.

Open study on PubMed →

The impact of quercetin and paclitaxel combination on ovarian cancer cells.

2024 · Treatment response

This study investigated the synergistic effects of quercetin and paclitaxel on ovarian cancer.

Open study on PubMed →

Resveratrol reduces lactate production and modifies the ovarian cancer immune microenvironment.

2022 · Immune and inflammatory signaling

Significantly, combined resveratrol and PD-1 blockade promote anti-tumor efficacy.

Open study on PubMed →

Silybin suppresses ovarian cancer cell proliferation by inhibiting isocitrate dehydrogenase 1 activity.

2022 · Tumor growth and proliferation

Here, we report that Silybin (a nontoxic flavonoid commonly used for liver protection) exhibits prominent anti-tumor effects on human ovarian cancer cells.

Open study on PubMed →

Scottsdale Clinic

14200 N Northsight Blvd #160
Scottsdale, Arizona 85260

Office Hours

Monday–Friday: 9:00 AM–5:00 PM
Saturday: 9:00 AM–12:00 PM

Visit Sunridge in Scottsdale

FREE INTRODUCTORY CALL

Speak With Our Patient Care Team

Tell us what you are facing. There is no charge to speak with our Patient Care Team, understand how Sunridge works and determine whether a physician consultation may be an appropriate next step.

Call Now: 1-800-923-7878

This introductory call is not a medical consultation and does not establish a physician-patient relationship.

Have a Question or Share Feedback:
It's easy to get in touch with us